Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/14602
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKeowkase R.
dc.contributor.authorAboukhatwa M.
dc.contributor.authorAdam B.-L.
dc.contributor.authorBeach J.W.
dc.contributor.authorTerry Jr. A.V.
dc.contributor.authorBuccafussco J.J.
dc.contributor.authorLuo Y.
dc.date.accessioned2021-04-05T03:35:55Z-
dc.date.available2021-04-05T03:35:55Z-
dc.date.issued2010
dc.identifier.issn17501326
dc.identifier.other2-s2.0-78650102379
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/14602-
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-78650102379&doi=10.1186%2f1750-1326-5-59&partnerID=40&md5=bab81db14b8d3f0e7ad154227eb3f3c5
dc.description.abstractBackground: Our previous work indicated that novel analogs of choline have cytoprotective effects in vitro that might be useful in neurodegenerative conditions such as Alzheimer's disease (AD). Furthermore, two lead compounds (JWB1-84-1 and JAY2-22-33) from a library of more than 50 improved cognitive performances in a transgenic mouse model of AD. The purpose of these experiments was to more specifically investigate the neuroprotective capabilities of these lead compounds both in vitro and in vivo. Results. We used N2a cells which express a Swedish mutation in the amyloid precursor protein and presenilin 1 genes to investigate the effect of JWB1-84-1 and JAY2-22-33 on -amyloid (A) levels and found that both compounds significantly reduced A levels. JWB1-84-1 and JAY2-22-33 also protected rat primary cortical neurons from A toxicity. Subsequently, we utilized the nematode Caenorhabditis elegans (C. elegans) as an in vivo model organism to identify potential molecular targets of these compounds. In the C. elegans model of A toxicity, human A is expressed intracellularly in the body wall muscle. The expression and subsequent aggregation of A in the muscle leads to progressive paralysis. Conclusion. We found that JAY2-22-33 (but not JWB1-84-1) significantly reduced A toxicity by delaying paralysis and this protective effect required both the insulin signaling pathway and nicotinic acetylcholine receptors (nAChRs). © 2010 Keowkase et al; licensee BioMed Central Ltd.
dc.subjectamyloid beta protein
dc.subjectamyloid precursor protein
dc.subjectcholine derivative
dc.subjectjay 2 22 33
dc.subjectjwb 1 84 1
dc.subjectnicotine derivative
dc.subjectpresenilin 1
dc.subjectunclassified drug
dc.subjectAlzheimer disease
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectarticle
dc.subjectbrain cell
dc.subjectCaenorhabditis elegans
dc.subjectcell culture
dc.subjectcognition
dc.subjectcontrolled study
dc.subjectdrug effect
dc.subjectdrug structure
dc.subjectdrug targeting
dc.subjectgene mutation
dc.subjecthuman
dc.subjecthuman cell
dc.subjectin vitro study
dc.subjectin vivo study
dc.subjectneuroprotection
dc.subjectnonhuman
dc.subjectprotein blood level
dc.subjectprotein expression
dc.subjectrat
dc.subjectCaenorhabditis elegans
dc.subjectMus musculus
dc.subjectRattus
dc.titleNeuroprotective effects and mechanism of cognitive-enhancing choline analogs JWB 1-84-1 and JAY 2-22-33 in neuronal culture and Caenorhabditis elegans
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationMolecular Neurodegeneration. Vol 5, No.1 (2010)
dc.identifier.doi10.1186/1750-1326-5-59
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.